cisplatin ebewe 0.5 mg/1 ml koncentrat za rastvor za infuziju
novartis ba d.o.o. - cisplatine - koncentrat za rastvor za infuziju - 0.5 mg/1 ml - 1 ml koncentrata za rastvor za infuziju sadrži: 0,5 mg cisplatina
cisplatin ebewe 0.5 mg/1 ml koncentrat za rastvor za infuziju
novartis ba d.o.o. - cisplatine - koncentrat za rastvor za infuziju - 0.5 mg/1 ml - 1 ml koncentrata za rastvor za infuziju sadrži: 0,5 mg
cisplatin sandoz 0.5 mg/1 ml koncentrat za rastvor za infuziju
sandoz d.o.o. - cisplatine - koncentrat za rastvor za infuziju - 0.5 mg/1 ml - 1 ml koncentrata za rastvor za infuziju sadrži: 0,5 mg cisplatina
cisplatin sandoz 0.5 mg/1 ml koncentrat za rastvor za infuziju
sandoz d.o.o. - cisplatine - koncentrat za rastvor za infuziju - 0.5 mg/1 ml - 1 ml koncentrata za rastvor za infuziju sadrži: 0,5 mg cisplatina
vepesid 100 mg meke kapsule
cheplapharm arzneimittel gmbh, ziegelhof 24, greifswald, njemačka - etoposidum - kapsula, meka - 100 mg - urbroj: jedna meka kapsula sadrži 100 mg etopozida
tecentriq 840mg/14ml koncentrat za rastvor za infuziju
"hoffmann-la roche ltd" d.s.d. podgorica - atezolizumab - koncentrat za rastvor za infuziju - 840mg/14ml
tecentriq 1200mg/20ml koncentrat za rastvor za infuziju
"hoffmann-la roche ltd" d.s.d. podgorica - atezolizumab - koncentrat za rastvor za infuziju - 1200mg/20ml
imfinzi
astrazeneca ab - durvalumab - karcinom, ne-malih stanica pluća - antineoplastična sredstva - non-small cell lung cancer (nsclc)imfinzi as monotherapy is indicated for the treatment of locally advanced, unresectable non small cell lung cancer (nsclc) in adults whose tumours express pd-l1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum based chemoradiation therapy (see section 5. imfinzi in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic nsclc with no sensitising egfr mutations or alk positive mutations. small cell lung cancer (sclc)imfinzi in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (es-sclc). biliary tract cancer (btc)imfinzi in combination with gemcitabine and cisplatin is indicated for the first line treatment of adults with unresectable or metastatic biliary tract cancer (btc). hepatocellular carcinoma (hcc)imfinzi in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc).
ciqorin 10 mg meke kapsule
pliva hrvatska d.o.o., prilaz baruna filipovića 25, zagreb - ciclosporinum - kapsula, meka - 10 mg - urbroj: svaka meka kapsula sadrži 10 mg ciklosporina
ciqorin 100 mg meke kapsule
pliva hrvatska d.o.o., prilaz baruna filipovića 25, zagreb - ciclosporinum - kapsula, meka - 100 mg - urbroj: svaka meka kapsula sadrži 100 mg ciklosporina